Jecure Therapeutics

After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever
Endpoints
Tue, 09/21/21 - 10:47 am
Genentech
Jecure Therapeutics
NASH
RNA
858 Therapeutics
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
Sun, 01/13/19 - 11:32 am
NASH
Gilead Sciences
Merck
Roche
Novartis
Jecure Therapeutics
Pfizer
Celgene
Eli Lilly
Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics
Xconomy
Tue, 11/27/18 - 11:41 pm
Roche
Jecure Therapeutics
M&A
NASH
Genentech